Study of tumor-infiltrating lymphocyte for treatment of solid tumors.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Tumour infiltrating lymphocytes (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
- 05 Dec 2016 New trial record
- 28 Nov 2016 Lion Biotechnologies is planning to initiate a program of tumor-infiltrating lymphocyte for treatment of solid tumors during 2017.